We are pleased to announce that two exciting projects, brought to Keyholder by Longacre Funding Partners, have been approved by the Keyholder investment committee for final due-diligence and verification. These are Vaxeal and Celex.
Vaxeal is a second generation immunotherapy treatment based on Survivin and Cyclin B. It is for use in conjunction with front line treatments, to make immunotherapy safer and more effective. This is expected to have lower adverse side effects than current treatments, and effective against many cancers. It is also known to develop an immunity within some patients, making this an effective vaccine against cancer.
Investment in Vaxeal is expected to commence and be available to investors in July 2018.